Search research articles
Contact Us
Filters
Showing results (411-420 of 429) with videos related to
Page
of 43
Sort By:
AIDS (London, England)
|
February 24, 2001
The ADAM study continued: maintenance therapy after 50 weeks of induction therapy
M H Reijers, G J Weverling, S Jurriaans, et al.
Nederlands Tijdschrift Voor Geneeskunde
|
September 6, 2001
[HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy]
M Jambroes, G J Weverling, P Reiss, et al.
AIDS (London, England)
|
August 26, 1998
The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy
R M Hoetelmans, M H Reijers, G J Weverling, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
March 10, 2001
A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacy
D M Burger, P W Hugen, R E Aarnoutse, et al.
The Journal of Biological Chemistry
|
December 21, 2018
The catalytic mechanism of electron-bifurcating electron transfer flavoproteins (ETFs) involves an intermediary complex with NAD<sup/>
Gerrit J Schut, Nishya Mohamed-Raseek, Monika Tokmina-Lukaszewska, et al.
The Journal of Biological Chemistry
|
November 7, 2020
Correction: The catalytic mechanism of electron-bifurcating electron transfer flavoproteins (ETFs) involves an intermediary complex with NAD<sup>+</sup>
Gerrit J Schut, Nishya Mohamed-Raseek, Monika Tokmina-Lukaszewska, et al.
The Journal of Infectious Diseases
|
June 1, 1996
Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group
R T Schooley, C Ramirez-Ronda, J M Lange, et al.
Nature Chemical Biology
|
April 11, 2017
Mechanistic insights into energy conservation by flavin-based electron bifurcation
Carolyn E Lubner, David P Jennings, David W Mulder, et al.
Gastroenterology
|
August 31, 2010
Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus
Theodora E M S de Vries-Sluijs, Jurriën G P Reijnders, Bettina E Hansen, et al.
The Journal of Infectious Diseases
|
July 12, 2012
Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV
Roeland Zoutendijk, Hans L Zaaijer, Theodora E M S de Vries-Sluijs, et al.
Page
of 43
Search research articles
Search
Showing results (411-420 of 429) with videos related to
Sort By:
Page
of 43
AIDS (London, England)
|
February 24, 2001
The ADAM study continued: maintenance therapy after 50 weeks of induction therapy
M H Reijers, G J Weverling, S Jurriaans, et al.
Nederlands Tijdschrift Voor Geneeskunde
|
September 6, 2001
[HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy]
M Jambroes, G J Weverling, P Reiss, et al.
AIDS (London, England)
|
August 26, 1998
The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy
R M Hoetelmans, M H Reijers, G J Weverling, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
March 10, 2001
A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacy
D M Burger, P W Hugen, R E Aarnoutse, et al.
The Journal of Biological Chemistry
|
December 21, 2018
The catalytic mechanism of electron-bifurcating electron transfer flavoproteins (ETFs) involves an intermediary complex with NAD<sup/>
Gerrit J Schut, Nishya Mohamed-Raseek, Monika Tokmina-Lukaszewska, et al.
The Journal of Biological Chemistry
|
November 7, 2020
Correction: The catalytic mechanism of electron-bifurcating electron transfer flavoproteins (ETFs) involves an intermediary complex with NAD<sup>+</sup>
Gerrit J Schut, Nishya Mohamed-Raseek, Monika Tokmina-Lukaszewska, et al.
The Journal of Infectious Diseases
|
June 1, 1996
Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group
R T Schooley, C Ramirez-Ronda, J M Lange, et al.
Nature Chemical Biology
|
April 11, 2017
Mechanistic insights into energy conservation by flavin-based electron bifurcation
Carolyn E Lubner, David P Jennings, David W Mulder, et al.
Gastroenterology
|
August 31, 2010
Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus
Theodora E M S de Vries-Sluijs, Jurriën G P Reijnders, Bettina E Hansen, et al.
The Journal of Infectious Diseases
|
July 12, 2012
Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV
Roeland Zoutendijk, Hans L Zaaijer, Theodora E M S de Vries-Sluijs, et al.
Page
of 43